Merck KGaA begins phase 3 lupus skin treatment trial

April 30, 2026 8:05 AM

Merck KGaA, Darmstadt, Germany announced that the first patient received dosing in its phase 3 clinical program evaluating enpatoran for ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found